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Overview of Rulemaking Process 
 
RFI          ANPRM         NPRM         Final Rule 
 
 
public           public          public  
comment    comment      comment 
Regulatory Jurisdiction 
• “Research” “Quality Improvement” “Program” 
etc.? 
• Should all biospecimens research be covered? 
[“Human Subject”?] 
• Apply the regulations to all human subjects 
research at domestic institutions receiving 
Common Rule support? 
3 levels of review,  





“Excused” or “Registered” 
Convened IRB Review 
• Should continuing review no longer be 
required if the research is in the analysis or 
follow-up phase?  
• Should there be single IRB review of domestic 
sites of multi-site studies? 
• Should accountability requirements be set for 
the site institutions and the single IRB? 
Expedited Review 
• Should there be single expedited review of domestic 
sites of multi-site studies? 
• Revise the list of categories, and revise them again 
periodically? 
• Presume that the identified research procedures are 
minimal risk? 
• If eligible, should the research receive expedited review 
unless the reviewer refers it for a reason? 
• Should any of the .111 criteria be omitted? 
• Should continuing review occur only if  and when it is 
appropriate? 
 
“Excused” or “Registered” 
Research  
• Registration Form Submitted 
• Informed Consent (sometimes) 
• Data Security and Information Protection 
Standards applied 
• Sometimes audited retrospectively 
• May be referred for expedited or convened 
IRB review, depending on …..[X] 
Revising the scope of the existing exempt 
categories for “excused” or “registered” 
research 
• Expand category .101(b)(2) by removing the 
anonymity & risky response conditions for 
research involving competent adults? 
• Expand category .101(b)(4) by removing the 
“existing” & anonymous recording conditions? 
• Add a new category of benign interventions 
research? 
• Add other categories? 
 
How to improve informed consent 
Informed Consent 
• How could the Informed Consent process be 
improved? 
• Should written consent generally be required 
for research use of any biospecimens collected 
for clinical or research purposes? 
• Should “oral consent” be employed for some 
studies, e.g. surveys with competent adults, 
and, if so, how? 
 
Informed Consent (cont.) 
• Should investigators assess subjects’ 
understanding? 
• Should the criteria for waiver of informed 
consent be revised and clarified? 
• Should the criteria for waiver of 
documentation of informed consent be 
revised? 
Improving Informed Consent forms  
• Identify appropriate specific content that must 
be included?  
• Identify content that may not be included? 
• Identify how information should be presented? 
• Limit the acceptable length of various 
sections? 
• Make standardized consent form template(s) 
available?  
 
Research with Biospecimens 
 
Research with Biospecimens 
• What should the requirements be for research 
with specimens that already exist? 
• Should secondary research with biospecimens 
be “excused” from review unless there is a 
waiver of informed consent or if individual 
results will be returned to subjects? 
• Should research on de-identified biospecimens 
without consent or review be allowed? 
 
Research with Biospecimens (cont.) 
• What criteria should be used for waiver of 
consent for future research on biospecimens? 
• Should open-ended consent for future research 
with bio-specimens be implemented? 
• Should people be able to exclude certain types 






or Biospecimens  
Identifiable info and 
all biospecimens 
Limited data set (as 
defined in HIPAA  
Rule) 
Deidentified Info (as 
defined in HIPAA  
Rule) 




Yes, which could be 
obtained during initial 
collection 
No consent required No consent required 
IC for future research 
w/material collected 
for research? 
Yes, usually at time of 
consent for initial 
research (could be oral 
for data) 
Yes (same rule as 
“Identifiable info and 
all biospecimens”) 
Yes (same rule as 









Yes (same rule as 
“Identifiable info and 
all biospecimens” + 
prohibition on 
reidentification) 
Yes.  Protection would 
include prohibition on 
reidentification 
Registration of 
research w/IRB or 
research office? 
Yes Yes No 
Prior review by IRB 
or research office? 






• Should there be harmony with other regulations, 
including Subparts B, C, D, HIPAA, FDA, etc.? 
• Should we have a uniform set of Standards for 
Data Security and Information Protection, 
calibrated according to identifiability? 
• Should there be uniformity of guidance from all 
of the Common Rule agencies? 
• Should there be uniformity of information 
reported to the federal government? 
ANPRM Comments due 10/26/11 
Identify by docket ID number HHS-OPHS-2011-0005 
• Federal eRulemaking Portal: 
http://www.regulations.gov/  
• Mail/Hand delivery/Courier [For paper, disk, or CD-
ROM submissions] to: Jerry Menikoff, M.D., J.D., 
OHRP, 1101 Wootton Parkway, Suite 200, Rockville, 
MD 20852.  
Comments received, including any personal information, 
will be posted without change to 
http://www.regulations.gov/  
 
